Co-Director, Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus
Director, Neuroimmunology/MS Fellowship
Section Chief, Neuroimmunology
Research Interests
Clinical research in MS and related disorders
Teaching
Professor
(1994)
School of Medicine,
Neurology
Multiple sclerosis, Neuroimmunology
Publications
Alvarez E, Nair KV, Sillau S, Shelton I, Seale R, Selva S, Corboy J, Vollmer TL. Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions. Mult Scler J Exp Transl Clin. 2022 Jan-Mar;8(1):20552173211069359. PubMed PMID: 35024160
Vollmer BL, Wolf AB, Sillau S, Corboy JR, Alvarez E. Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis. Front Neurol. 2021;12:799138. PubMed PMID: 35145470
Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord. 2021 Oct;55:103170. PubMed PMID: 34364034
Piquet AL, Corboy JR, Vollmer TL. Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211019567. PubMed PMID: 34104219
Corboy JR, Jones EC, Barbano RL, Anderson DC. 2019-2020: A Message From the Editors to Our Reviewers. Neurol Clin Pract. 2021 Feb;11(1):e1-e5. PubMed PMID: 33968478
Strijbis EMM, Kerbrat A, Corboy JR. Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go? JAMA Neurol. 2021 Jul 1;78(7):787-788. doi: 10.1001/jamaneurol.2021.0764.PMID: 33871561
Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord. 2021 Jul 24;55:103170. doi: 10.1016/j.msard.2021.103170. Online ahead of print.PMID: 34364034
Strijbis EMM, Kerbrat A, Corboy JR. Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go?. JAMA Neurol. 2021 Jul 1;78(7):787-788. PubMed PMID: 33871561
Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders.Ann Clin Transl Neurol. 2020 Aug 6. doi: 10.1002/acn3.51136. Online ahead of print. PMID: 32767531
Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 Aug 6. doi: 10.1002/acn3.51111. Online ahead of print. PMID: 32767538
Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL, Ford C, Weinstock-Guttman B, Bar-Or A, Mientus S, Sienkiewicz D, Zhang Y, Karan R, Tenenbaum N; Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. ASSESS Trial Investigators. JAMA Neurol. 2020 Aug 24:e202950. doi: 10.1001/jamaneurol.2020.2950. Online ahead of print.PMID: 32852530
Wu Q, Mills EA, Wang Q, Dowling CA, Fisher C, Kirch B, Lundy SK, Fox DA, Mao- Draayer Y. Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis.; AMS04 Study Group.JCI Insight. 2020 Feb 13;5(3). pii: 134251. doi: 10.1172/jci.insight.134251. PMID: 31935197
Cree BAC, Cutter G, Wolinsky JS, et al SPI2 investigative teams. Safetyand efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2020 Dec;19(12):988-997. doi: 10.1016/S1474-4422(20)30347-1. Epub 2020 Oct 23.PMID: 33222767
Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL, Ford C, Weinstock-Guttman B, Bar-Or A, Mientus S, Sienkiewicz D, Zhang Y, Karan R, Tenenbaum N; Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. ASSESS Trial Investigators. JAMA Neurol. 2020 Aug 24; 78(1):1-13. doi: 10.1001/jamaneurol.2020.2950. Online ahead of print. PMID: 32852530
Honce JM, Nair KV, Hoyt BD, Seale RA, Sillau S, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Alvarez E. Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. Front Neurol. 2020 Sep 23;11:1045. doi: 10.3389/fneur.2020.01045. eCollection 2020.PMID: 33071934
Waid DM, Schreiner T, Vaitaitis G, Carter JR, Corboy JR, Wagner DH Jr. Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells. J Neuroimmunol. 2014 Mar 15. [Epub ahead of print] PubMed PMID: 24690203
Lafosse JM, Mitchell SM, Corboy JR, Filley CM. The nature of verbal memory impairment in multiple sclerosis: a list-learning and meta-analytic study. J Int Neuropsychol Soc. 2013 Oct;19(9):995-1008. PubMed PMID: 24059259
Mattson DH, Lisak RP, Jones DE, Corboy JR, Larson R, Gronseth G, Getchius TS, Langer-Gould A, Langer-Gould AM, Gronseth GS, Larson R, Getchius TS. The American Academy of Neurology's top five Choosing Wisely recommendations. Neurology. 2013 Sep 10;81(11):1022-3. PubMed PMID: 24019388
Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Am J Manag Care. 2013 Apr;19(4):278-85. PubMed PMID: 23725360
Hebert JR, Corboy JR. The association between multiple sclerosis-related fatigue and balance as a function of central sensory integration. Gait Posture. 2013 May;38(1):37-42. PubMed PMID: 23200463
Clinical Interests
Multiple Sclerosis, other neuroimmunological disorders, HIV in Nervous System, Infections and Inflammatory Disorders of the Central Nervous System
Care Philosophy
Multidisciplinary care for MS and related diseases. We believe in aggressive treatment of MS with disease modifying and symptomatic therapies.
Personal Interests
Skiing, golf, ice hockey, travel.
Volunteer Activities
Board member, National MS Society, Colorado-Wyoming Chapter
Volunteer MS clinic at Denver Health Medical Center
Advocacy at State and National level for access to health care
Public Speaking Yes
MS Education at multiple levels
General Information
Medical Schools:
MD, University of Pennsylvania School of Medicine
(1985)
Graduate Schools:
MA, University of California, Los Angeles
(1978)
Undergraduate Schools:
BA, University of Pennsylvania (Philadelphia, PA)
(1976)
Internships:
University of Pennsylvania Program
(1986)
Residency Programs:
University of Pennsylvania Health System Program, Chief Resident, Psychiatry (1989)
Fellowships:
Johns Hopkins University Program, Neurovirology
(1992)